Cognitive Function in Patients With Persisted Atrial Fibrillation

NCT ID: NCT04508491

Last Updated: 2026-01-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-30
• Study Completion Date: 2025-02-26

Brief Summary

Compare the difference of cognitive function between different treatment strategy in patients with persistent atrial fibrillation

Detailed Description

The prevalence of atrial fibrillation (AF) had been increasing for the past decade. The increase of AF was attributed to the aging of the population and the increased awareness of the disease among people and the primary physicians. However, we have not achieved the consensus whether aggressive rhythm control or conservative rate control is better in a patient with asymptomatic persisted AF. We do prescribe anti-coagulant for stroke prevention, but which treatment strategy is best for the patients is uncertain.

The clinical trial of catheter-based ablation for rhythm control compared to traditional medication control has not shown the benefit of reducing all-cause mortality, but it did show a reduction of re-hospitalization and the recurrence of AF. On the contrary, the study in heart failure patients had shown a significant benefit applying catheter-based rhythm control strategy to reduce all-cause mortality. The different results of these two trials told us the benefit of rhythm control is not easily to be seen in a short-term, but could be seen in a long term or in high risk patients. The association between AF and cognitive impairment has also been reported in observation cohort. However, there is no sold evidence in clinical trials to show the improvement of cognitive function by treating atrial fibrillation. One study did show improvement of cognitive function with questionnaire, but the other showed new lesion detected by traditional magnetic resonance imaging (MRI) after ablation, though the lesion resolved after one year of follow-up. There is no clear answer to which treatment strategy is better for the patients' cognitive function。 Therefore, we designe a prospective, randomized, blind endpointtrial. We will enroll the patients with persisted AF, and use advanced MRI (DTI/SWI) and questionnaire to longitudinally study the cognitive function change of the patients before and after the initiation of anti-coagulant agents, before and after the catheter-based ablation, and use this as a surrogate to understand the best treatment strategy for these AF patients.

Conditions

Atrial Fibrillation, Persistent; Cognitive Function

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Rhythm control

Rhythm control with medication or any procedure

Group Type: EXPERIMENTAL

Rhythm control

Intervention Type: OTHER

Rhythm control with medications or any procedure

Rate control

Rate control with medication or any procedure

Group Type: ACTIVE_COMPARATOR

Rate control

Intervention Type: OTHER

Rate control

Interventions

Rhythm control

Rhythm control with medications or any procedure

Intervention Type: OTHER

Rate control

Rate control

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Those who meet the diagnosis of persistent atrial fibrillation, meet one of the following conditions:

• The twelve-lead electrocardiogram is used to diagnose atrial fibrillation, and to cooperate with clinical diagnosis.
• 24 hours ECG diagnosis 100% atrial fibrillation, with clinical diagnosis.
• The seven-day ECG recorder diagnosed 100% atrial fibrillation.

2. Willing to accept treatment recommended by doctors, containing anticoagulant, and cooperate with examination and treatment in the coming year.

Exclusion Criteria

1. Unwilling to sign the clinical trial consent form.

2. Unable to complete the cognitive function questionnaire.

3. Unable to complete brain MRI examination due to various reasons

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Taiwan University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

National Taiwan University Hospital

Taipei, , Taiwan

Countries

Taiwan

Other Identifiers

201912175RINC

Identifier Type: -

Identifier Source: org_study_id